Liraglutide vs. Sitagliptin for Type 2 Diabetes
Author Information
Author(s): Richard Pratley, Michael Nauck, Timothy Bailey, Eduard Montanya, Richard Cuddihy, Silvio Filetti, A. Garber, Anne B. Thomsen, H. Hartvig, M. Davies
Primary Institution: University of Vermont College of Medicine
Hypothesis
The study aims to compare the efficacy and safety of liraglutide and sitagliptin, both added to metformin, over 52 weeks in individuals with type 2 diabetes.
Conclusion
Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks compared to sitagliptin.
Supporting Evidence
- Liraglutide reduced HbA1c by −1.29% and −1.51% compared to −0.88% with sitagliptin.
- Weight loss was greater with liraglutide (−2.78 kg and −3.68 kg) than with sitagliptin (−1.16 kg).
- Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin.
Takeaway
This study shows that taking liraglutide helps people with type 2 diabetes control their blood sugar and lose weight better than sitagliptin.
Methodology
Participants were randomized to receive either liraglutide (1.2 mg or 1.8 mg) or sitagliptin (100 mg) while continuing metformin for 52 weeks.
Potential Biases
Potential conflicts of interest due to funding and author disclosures.
Limitations
The study lacked a placebo group and was not double-blinded.
Participant Demographics
Participants were adults with type 2 diabetes previously treated with metformin.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: −0.59 to −0.22 for 1.2 mg and −0.81 to −0.44 for 1.8 mg
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website